1 |
Traxler P, Allegrini PR, Brandt R et al : AEE788 : A dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 64 : 4931, 2004
DOI
ScienceOn
|
2 |
Parkin DM, Pisani P, Ferlay J : Global cancer statistics. CA Cancer J Clin 49 : 33, 1999
DOI
ScienceOn
|
3 |
Rubin GJ : Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90 : 824, 1998
DOI
ScienceOn
|
4 |
Nicoletti I, Migliorati G, Pagliacci MC et al Z : A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139 : 271, 1991
DOI
ScienceOn
|
5 |
Yarden Y, Sliwkowski MX : Untangling the ErbB signaling network. Nat Rev Cell Biol 2 : 127, 2001
DOI
ScienceOn
|
6 |
Woodburn JR : The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82 : 241, 1999
DOI
ScienceOn
|
7 |
Nihei Y, Suzuki M, Okano A et al : Evaluation of antivascular and antitumor effects of tubulin binding agents in solid tumor therapy. Jap J Cancer Res 90 : 1387, 1999
DOI
|
8 |
Pollack VA, Savage DM, Baker DA et al : Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358, 774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 291 : 739, 1999
|
9 |
Salomon DS, Brandt R, Ciardiello F et al : Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19 : 183, 1995
DOI
ScienceOn
|
10 |
Magne N, Fischel JL, Dubreuil A : Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer. Br J Cancer 86 : 819, 2002
DOI
ScienceOn
|
11 |
Williams KJ, Telfer BA, Stratford IJ et al : ZD1839 ('Iressa'), a specific oral epidermal growth factor receptortyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer 86 : 1157, 2002
DOI
ScienceOn
|
12 |
Baillie R : Expression of vascular endothelial growth factor in normal and tumour oral tissues assessed with different antibodies. Histochem J 33 : 287, 2001
DOI
ScienceOn
|
13 |
Rusch V : Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 3 : 515, 1997
|
14 |
Ciardiello F, Tortora G : A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7 : 2958, 2001
|
15 |
Michi Y : Human oral squamous cell carcinoma cell lines promote angiogenesis via expression of vascular endothelial growth factor and upregulation of KDR/flk-1 expression in endothelial cells. Oral Oncol 36 : 81, 2000
DOI
ScienceOn
|
16 |
Huang SM, Bock JM, Harari PM : Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59 : 1935, 1999
|
17 |
Kawakami K, Tsukuda M, Mizuno H et al : Alteration of the Bcl-2/bax status of head and neck cancer cell lines by chemotherapeutic agents. Anticancer Res 19 : 3927, 1999
|
18 |
Baselga J, Rischin D, Ranson M : Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20 : 4292, 2002
|
19 |
Swan EA, Jasser SA, Holsinger FC et al : Acquisition of anoikis resistance is a critical step in the progression of oral tongue cancer. Oral Oncol 39 : 648, 2003
DOI
ScienceOn
|
20 |
Herbst RS, Shin DM : Monoclonal antibodies to target epidermal growth factor receptor-positive tumors (a new paradigm for cancer therapy). Cancer 94 : 1593, 2002
DOI
ScienceOn
|
21 |
Matsuno F, Haruta Y, Kondo M et al : Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new antiendoglin monoclonal antibodies. Clin Cancer Res 5 : 371, 1999
|
22 |
Nelson JM, Fry DW : Akt, MAPK (Erk1/2), and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition. J Biol Chem 276 : 14842, 2001
DOI
ScienceOn
|
23 |
Goepfert H : Squamous cell carcinoma of the head and neck: past progress and future promise. CA Cancer J Clin 48 : 195, 1998
DOI
ScienceOn
|
24 |
Neuchrist C, Erovic BM, Handisurya A et al : Vascular endothelial growth factor receptor 2 (VEGFR2) expression in squamous cell carcinomas of the head and neck. The Laryngoscope 111 : 1834, 2001
DOI
ScienceOn
|
25 |
Lynch TJ, Bell DW, Sordella R et al : Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 350 : 2129, 2004
DOI
ScienceOn
|
26 |
Molena G, De Meijer DK, Leij LF : Tumor vasculature targeted therapies: getting the players organized. Biochem. Pharmacol 55 : 1939, 1997
DOI
ScienceOn
|
27 |
O-charoenrat P, Phys-Evans PH, Archer DJ et al : C-erbB receptors in squamous cell carcinomas of the head and neck: clinical significance and correlation with matrix metalloproteinases and vascular endothelial growth factors. Oral Oncol 38 : 73, 2002
DOI
ScienceOn
|
28 |
Myers JN, Holsinger FC, Bekele BN : Targeted molecular therapy for oral cancer with epidermal growth factor receptor blockade. Arch Otolaryngol Head Neck Surg 128 : 875, 2002
DOI
|
29 |
Cohen EE, Rosen F, Stadler WM et al : Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21 : 1980, 2003
DOI
ScienceOn
|
30 |
Wedge SR, Ogilvie DJ, Dukes M et al : ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62 : 4645, 2002
|
31 |
Werkmeister R, Brandt B, Joos U : Clinical relevance of erbB-1 and -2 oncogenes in oral carcinomas. Oral Oncol 36 : 100, 2000
DOI
ScienceOn
|
32 |
Ford AC, Grandis JR : Targeting epidermal growth factor receptor in head and neck cancer. Head Neck 25 : 67, 2003
DOI
ScienceOn
|
33 |
Kerr DJ, Maughan T, Newlands E et al : Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma. Br J Cancer 60 : 104, 1989
DOI
ScienceOn
|
34 |
Santini J : Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 13 : 132, 1991
DOI
ScienceOn
|
35 |
Jones AS : Neoplastic chemotherapy and head and neck cancer. J Laryngol Otol 111 : 607, 1997
|
36 |
Well SA : EGF receptor. Int J Biochem Cell Biol 31 : 637, 1999
DOI
ScienceOn
|
37 |
Neuchrist C, Quint C, Pammer A et al : Vascular endothelial growth factor (VEGF) and microvessel density in squamous cell carcinomas of the larynx: an immunohistochemical study. Acta Otolaryngol 119 : 732, 1999
DOI
ScienceOn
|
38 |
Mekhail TM, Markamn M : Paclitaxel in cancer therapy. Exper Opin Pharmacother 3 : 755, 2002
DOI
ScienceOn
|